Publications by authors named "Marcia T Delamain"

Article Synopsis
  • RTXM83, a biosimilar to rituximab, has been approved after extensive studies showed it is similar to the original drug; this includes results from a pivotal study called RTXM83-AC-01-11.
  • A retrospective study in Brazil analyzed long-term outcomes for patients with diffuse large B cell lymphoma (DLBCL) who received either RTXM83 or the original rituximab alongside other chemotherapy drugs, revealing that both groups showed significant progress in treatment.
  • The findings highlighted that RTXM83 had a much higher progression-free survival and overall survival rate compared to the original drug, indicating its effectiveness and safety, although further research is needed to confirm these results in
View Article and Find Full Text PDF
Article Synopsis
  • - Marginal zone lymphomas (MZL) are a group of related subtypes that currently lack a standardized prognostic score for patients requiring systemic therapy.
  • - Researchers developed a prognostic model based on a study of 501 patients, identifying five important factors that significantly affect progression-free survival (PFS) and creating three risk categories: low, intermediate, and high.
  • - The newly proposed MZL International Prognostic Index (MZL-IPI) has been validated in multiple patient cohorts, showing reliable predictive value for both PFS and overall survival (OS) among MZL patients undergoing treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and relies on angiogenesis, mainly driven by VEGFA and VEGFR2.
  • A study was conducted on 168 DLBCL patients and 205 controls to see how certain single nucleotide variants (SNVs) affect DLBCL risk and angiogenic traits.
  • Findings revealed that specific genotypes, such as -1154GG, +1192GG with +1719TT, and +1192GG with -2578CC, significantly increased DLBCL risk, while -634GG or GC genotypes were linked to higher levels of blood vessel density and VEGFA.
View Article and Find Full Text PDF

Castleman's disease (CD) is a rare and heterogeneous lymphoproliferative disorder, with limited available clinical information in Brazil. A retrospective study was carried out through information contained in the medical records of 51 patients, between July 1999 and June 2020. Seven patients were excluded, and 44 were analyzed in total.

View Article and Find Full Text PDF

Purpose: Isolated case reports mention the uptake of radiolabeled PSMA in lymphoma. However, it is not clear if the intensity of 68Ga-PSMA expression varies among different histological subtypes or if it correlates with 18F-FDG uptake. This study compared both tracers in patients with diverse lymphoma subtypes.

View Article and Find Full Text PDF

Objectives: Single nucleotide variants (SNVs) in vascular endothelial growth factor A (VEGFA) and VEGFA receptor (KDR) genes confer different inherited abilities in angiogenesis (AG) pathway. We aimed in the present study to evaluate influence of six VEGFA and four KDR SNVs in clinical features and survival of diffuse large B-cell lymphoma (DLBCL) patients.

Methods: One hundred and sixty-eight DLBCL patients diagnosed between June 2009-September 2014 were enrolled in the study.

View Article and Find Full Text PDF

Background: There is evidence to consider that the tumor microenvironment (TME) composition associates with antitumor immune response, and may predict the outcome of various non-Hodgkin lymphoma subtypes. However, in the case of mantle cell lymphoma (MCL), a rare and aggressive disease, there is lacking a detailed study of the TME components, as well as an integrative approach among them in patients' samples. Also, from the genetic point of view, it is known that single nucleotide variants (SNVs) in immune-response genes are among important regulators of immunity.

View Article and Find Full Text PDF

Purpose: To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL).

Methods: We conducted the prospective Elderly Project study on patients with DLBCL older than 64 years who underwent our Fondazione Italiana Linfomi original geriatric assessment (oGA) (age, Cumulative Illness Rating Scale for Geriatrics, activities of daily living, and instrumental activities of daily living) before treatment. Treatment choice was left to the physician's discretion.

View Article and Find Full Text PDF

The study of the tumor microenvironment (TME) in follicular lymphoma (FL) has produced conflicting results due to assessment of limited TME subpopulations, and because of heterogeneous treatments among different cohorts. Also, important genetic determinants of immune response, such as single-nucleotide polymorphisms (SNPs), remain underexplored in this disease. We performed a detailed study of the TME in 169 FL biopsies using immunohistochemistry, encompassing lymphocytes, macrophages, and cytokines.

View Article and Find Full Text PDF

Purpose: F-fluorodeoxiglucose (F-FDG)-PET/CT has been widely used to evaluate multiple myeloma. Tc-sestamibi (MIBI) scintigraphy has also been proposed for assessing multiple myeloma, but its use with state-of-the-art single-photon emission computed tomography/computed tomography (SPECT/CT) technology has not been fully evaluated.This study aimed to compare these two imaging modalities in multiple myeloma staging.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 outbreak is classified as a global pandemic, impacting over 1.3 million individuals globally.
  • Cancer patients, especially those with lymphoid malignancies, face increased risks of severe illness, including ICU admission and higher mortality rates.
  • The article discusses strategies for managing patients with lymphoid malignancies during the pandemic, emphasizing the importance of minimizing their risk during treatments that often require frequent medical visits.
View Article and Find Full Text PDF

Background: Although the increased use of combined antiretroviral therapy (cART) has decreased the incidence of lymphomas HIV-associated, Burkitt lymphoma (BL) incidence remains stable. Reported outcomes on HIV-associated BL from developed countries seem to corroborate that the regimens do not need to be tailored to the HIV-positive population.

Materials And Methods: This is a retrospective multicenter cohort study from Brazil, including HIV-positive patients aged 15 years and above diagnosed with BL.

View Article and Find Full Text PDF

Quantification of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) can be time-consuming. We evaluated the performance of an automatic multifocal segmentation (MFS) method of quantification in patients with different stages of Hodgkin lymphoma, using the multiple VOI (MV) method as reference. This prospective bicentric study included 50 patients with Hodgkin lymphoma who underwent staging F-FGD PET/CT.

View Article and Find Full Text PDF

Introduction: The incidence of grade 3-4 anemia was reported to be 3% with imatinib therapy for newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). However, there are few data regarding the causes and the development of anemia after long-term treatment. This study aimed to evaluate the incidence of anemia after at least two years of imatinib treatment of CML patients in the CP and to identify other contributing causes of anemia in this population.

View Article and Find Full Text PDF

This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffuse large B-cell lymphoma (DLBCL). A total of 272 patients <65 years of age, with good prognosis (136 per arm) were randomized (1:1) to receive six cycles of either RTXM83 or R-rituximab.

View Article and Find Full Text PDF

We analyzed the management and outcomes of pregnancies of patients with chronic myeloid leukemia at a single center over fifteen years. Among the 203 CML female patients, there were ten pregnancies in seven women, all of them not planned. In three cases, the chronic myeloid leukemia diagnosis was made during pregnancy.

View Article and Find Full Text PDF

We describe the case of a female patient, 52 years old, with dizziness and left motor incoordination for 2 weeks. Brain MRI magnetic resonance imaging) revealed a hyperintense lesion on T2-weighted images, without restricted diffusion, in the left middle cerebellar peduncle. Spectroscopy demonstrated peak of lipids and perfusion did not show any elevation in relative cerebral blood volume (rCBV).

View Article and Find Full Text PDF

Background: Cardiovascular events (CVEs) have been observed in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors.

Patients And Methods: We retrospectively evaluated the incidence of CVEs on 233 consecutive patients with chronic myeloid leukemia, of which 116 were treated with imatinib, 75 with dasatinib, and 42 with nilotinib. The median follow-up was 2047, 1712, and 1773 days, respectively.

View Article and Find Full Text PDF

Objective: Follicular and mantle cell lymphoma are low-grade B-cell malignancies that lack good responses to chemoimmunotherapy. This study aimed to assess retrospectively clinicopathological features and to determine independent prognostic factors for follicular and mantle cell lymphoma patients treated at two Brazilian medical centers: the Hematology and Hemotherapy Center of the Universidade Estadual de Campinas (Unicamp), a public university hospital, and AC. Camargo Cancer Center, a specialized cancer center.

View Article and Find Full Text PDF